Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rose about 30% over 21 sessions and 36% from September 10 to September 17. Positive cancer-vaccine validation, the planned Personalis acquisition, new product and FDA milestones, and first-time positive adjusted EBITDA support the move.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Rebound ⢠Negative Cash Flow ⢠Rising Leverage TEM's profitability improved sharply in the latest quarter, but persistent cash burn, rising leverage, and a demanding valuation warrant caution despite strong liquidity.
Price Behavior
Key Price Behavior Insights: ⢠Strong breakout ⢠Resistance rejection ⢠Key support Support Level: $68.00â$70.00 Resistance Level: $80.00â$81.00 TEM gained 17% over the last month but faces pullback risk near $80â81 resistance, with $68â70 key support to hold.
Sentiment & News
Key News Insights: ⢠Analyst upgrades ⢠ARPA-H funding ⢠Valuation caution Tempus AI's surge reflects analyst optimism, AI-healthcare catalysts and Merck-related momentum, though its rapid run-up raises near-term valuation risk.
AI Summary
TEM's investment case has shifted to a reimbursement-driven operating-leverage story, but at ~$80 investors should wait for proof that xT/xF reimbursement converts into sustained positive operating cash flow, as a shortfall in payer adoption or Personalis integration could sharply pressure its premium valuation.
Description
Tempus AI, Inc. is a healthcare technology company that performs molecular diagnostics, including next-generation sequencing, PCR profiling, genotyping and anatomic pathology for healthcare providers, pharmaceutical and biotechnology firms, and researchers. It also licenses a de-identified, linked clinicalâmolecularâimaging dataset and offers analytics, cloud compute tools, clinical trial matching, algorithmic oncology tests and software for test ordering and research workflows. The company entered strategic collaborations with AstraZeneca and Pathos AI, was incorporated in 2015, changed its name from Tempus Labs in January 2023, and is headquartered in Chicago, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 17 | Sep 24 | TEM | Tempus AI, Inc. | Rose about 30% over 21 sessions and 36% from September 10 to September 17. Positive cancer-vaccine validation, the planned Personalis acquisition, new product and FDA milestones, and first-time positive adjusted EBITDA support the move. | Closed | +2.3% |
| Dec 9 | Dec 16 | TEM | Tempus AI, Inc. | Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential. | Closed | -10.2% |